Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2018 Annual Meeting of Stockholders held by Oramed Pharmaceuticals Inc. on August 28, 2018. The filing covers the voting outcomes for director elections, executive compensation, and auditor ratification.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting results.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1: Re-election of Directors. All seven nominees were re-elected. Significant broker non-votes (7,359,443) were recorded for all candidates. Director Xiaopeng Li received the highest number of "Against" votes (232,414) compared to other nominees.
- Proposal 2: Advisory Vote on Executive Compensation. Stockholders approved the compensation of Named Executive Officers. The vote was split, with 3,661,606 votes "For" and 889,122 votes "Against."
- Proposal 3: Ratification of Auditors. Stockholders ratified the appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) as the independent registered public accounting firm for the fiscal year ending August 31, 2018. The vote was overwhelmingly in favor with 11,638,832 "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote versus the number of shares represented at the meeting to assess participation rates.
- Note the high volume of broker non-votes (7,359,443) on director elections, which indicates a significant portion of shares held in street name did not receive voting instructions.
- Review the "Against" vote count for Director Xiaopeng Li (232,414), which was notably higher than for other directors.
- Confirm the approval of the executive compensation advisory vote, which received approximately 19% "Against" votes.